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MaBACKGROUND Multiple equations exist to estimate glomerular ﬁltration rate (GFR); however, there is no consensus
on which is superior for risk classiﬁcation in patients with chronic kidney disease (CKD) undergoing percutaneous coronary
intervention (PCI).
OBJECTIVES The goals of this study were to identify which equation to estimate GFR is superior for predicting adverse
outcomes after PCI and to examine how equation selection would impact drug-dosing recommendations.
METHODS Estimated GFR (eGFR) was calculated with the Cockcroft-Gault, Modiﬁcation of Diet in Renal Disease
Study (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations for 128,805 patients
undergoing PCI in the state of Michigan. Agreement between patient pre-PCI eGFR estimates and resultant CKD stage
classiﬁcations, their ability to discriminate post-procedural in-hospital clinical outcomes, and the impact of equation
choice on dosing recommendations for commonly used antiplatelet and antithrombotic medications were investigated.
RESULTS CKD-EPI best discriminated post-PCI mortality by receiver operator characteristic analysis. There was
wide variability in eGFR, which persisted after grouping by CKD stages. Reclassiﬁcation by CKD-EPI resulted in net
reclassiﬁcation index improvement for acute kidney injury and new requirement for dialysis. Equation choice affected
drug-dosing recommendations, with the formulas agreeing for only 50.3%, 40.0%, and 34.3% of potentially impacted
patients for eGFR cutoffs of <60, <50, and <30 ml/min/1.73 m2, respectively.
CONCLUSIONS Different eGFR equations result in CKD stage reclassiﬁcation that has major clinical implications for
predicting adverse outcomes after PCI and drug-dosing recommendations. Our results support the use of CKD-EPI for risk
stratiﬁcation among patients undergoing PCI. (J Am Coll Cardiol 2015;65:2714–23) © 2015 by the American College of
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2715AB BR E V I A T I O N S
AND ACRONYM S
AKI = acute kidney injury
BIS1 = Berlin Initiative Study
CKD = chronic kidney disease
CKD-EPI = Chronic Kidney
Disease Epidemiology
Collaboration
eGFR = estimated glomerular
ﬁltration rate
GFR = glomerular ﬁltration
rate
KDIGO = Kidney Disease
Improving Global Outcomes
MDRD = Modiﬁcation of Diet in
Renal Disease
NRD = new requirement for
dialysis
NRI = net reclassiﬁcation index
PCI = percutaneous coronary
interventionF or patients with acute coronary syndrome whoundergo percutaneous coronary intervention(PCI), chronic kidney disease (CKD) and
advanced age are associated with an increased risk
of adverse outcomes, including in-hospital mortality,
bleeding, and acute kidney injury (1–3). Estimated
glomerular ﬁltration rate (eGFR), the most common
method used to diagnose and stage CKD, can be
calculated by several equations, including the
Cockcroft-Gault equation, the Modiﬁcation of Diet in
Renal Disease (MDRD) Study equation, and the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation (4–6). The Berlin Initiative Study
(BIS1) equation was developed recently in adults
$70 years of age in an attempt to more accurately pre-
dict eGFR in this subgroup (7). The 2012 Kidney Disease
Improving Global Outcomes (KDIGO) guidelines
recommend that clinicians use CKD-EPI because of
its superior accuracy (8). The Cockcroft-Gault equation
is no longer recommended because it was developed
before the standardization of creatinine assays and is
less accurate (9); however, the preference for which
estimate to use varies widely among institutions, and
the Cockcroft-Gault equation is still often used in
clinical practice and in pharmacokinetic studies (10).SEE PAGE 2724Although others have shown that the use of
different equations can result in CKD stage reclas-
siﬁcation, it is unclear how this would impact
prognostication for patients undergoing PCI. We
investigated whether the use of different eGFR
equations would result in different CKD staging of
patients undergoing PCI and examined how reclassi-
ﬁcation correlates with risk of adverse events after
PCI. We then extended our analysis to determine how
differences in CKD classiﬁcation would affect the
dosing of commonly used antiplatelet and antith-
rombotic agents in the catheterization laboratory.
METHODS
We performed a retrospective post-hoc analysis using
data from the Blue Cross Blue Shield of Michigan
Cardiovascular Consortium, a regional registry of all
patients undergoing PCI at nonfederal hospitals in
Michigan. A detailed outline of the registry has been
described previously (11). To summarize, this is a
prospective, multicenter, statewide registry of pa-
tients undergoing PCI at 47 participating centers. For
our present study, consecutive patients undergoing
emergent or elective PCI between January 2010 and
March 2014 were included. We excluded all patients
who required hemodialysis before PCI, those withincomplete data on serum creatinine levels
before or after PCI, and those without both a
height and weight recorded. Pre-procedural
serum creatinine values were measured
within 30 days before PCI, with the value
closest to the time of PCI chosen as the base-
line value. Peak post-procedural creatinine
was deﬁned as the highest value after PCI and
before the next procedure or discharge.
ESTIMATION OF GLOMERULAR FILTRATION
RATE. For our population of all-comers, we
calculated eGFR using the Cockcroft-Gault,
MDRD, and CKD-EPI equations. Each equation
is provided with a summary of its develop-
mental cohort in Table 1. The Cockcroft-Gault
equation calculates creatinine clearance and
not eGFR; however, its output has been
compared in the literature with the eGFR
of other equations, both with and without
adjustment for body surface area (12,13). We
performed our analysis with the unadjusted
Cockcroft-Gault output and an additional analysis with
Cockcroft-Gault adjusted for body surface area by
normalizing the output per 1.73 m2 of body surface
area (identical to the normalization of the glomerular
ﬁltration rate [GFR] measurement) (14). Additionally,
because of unclear recommendations for body weight,
estimation of eGFR by Cockcroft-Gault was calculated
twice, with both actual and ideal body weight (15). For
analysis of the subgroup of patients $70 years of age,
eGFR was also calculated by the BIS1 equation.
STUDY ENDPOINTS. The diagnostic accuracy of can-
didate eGFR estimates was evaluated with respect to
4 in-hospital clinical outcomes, including the primary
endpoint of acute kidney injury (AKI) and secondary
endpoints of new requirement for dialysis (NRD),
in-hospital mortality, and receipt of transfusion.
AKI was deﬁned as a $0.5 mg/dl increase in absolute
serum creatinine from the baseline pre-procedural
value (16,17). NRD was deﬁned as any new, un-
planned need for dialysis after PCI. In-hospital mor-
tality was deﬁned as mortality attributable to any
cause during the initial hospitalization after PCI.
Receipt of transfusion was deﬁned as the transfusion
of whole blood or packed red blood cells from the
time of PCI to before discharge or death.
STATISTICAL ANALYSIS AND DATA VISUALIZATION.
Scatterplots comparing the eGFRs were used to
visualize disagreement between eGFR estimates at
the patient level. Estimated eGFRs values were win-
sorized (censored) at 200 ml/min for convenience in
graphic representation and to prevent the undue in-
ﬂuence of large-value outliers on the analysis. Lin’s
TABLE 1 Equations for Estimating GFR and CrCl
Name Equation Author, Year (Ref. #) Developmental Cohort Summary
Cockcroft-Gault CrCl ¼ [(140  age)  weight*] /
72  SCr ( 0.85 if female)
Cockcroft and Gault, 1976 (4) n ¼ 249, mean age not provided, % male ¼ 100,
% black ¼ 0, % diabetic not provided, average
weight ¼ 72 kg, mean CrCl not provided
MDRD eGFR ¼ 175  SCr1.154  age0.203  0.742
(if female)  1.21 (if black)
Levey et al., 1999 (5) n ¼ 1,628, mean age ¼ 50.6  12.7 yrs, % male ¼ 60,
% black ¼ 12, % diabetic ¼ 6, mean weight ¼
79.6  16.8 kg, mean GFR ¼ 39.8
CKD-EPI eGFR ¼ 141  min (SCr / k,1)a 
max(SCr / k,1)1.209  0.993Age  1.018
(if female)  1.159 (if black)†
Levey et al., 2009 (6) n ¼ 5,504, mean age ¼ 47  15 yrs, % male ¼ 57,
% black ¼ 32, % diabetic ¼ 29, average weight ¼
82  0 kg, mean GFR ¼ 68  40
BIS1 eGFR ¼ 3736  SCr0.87  age0.95  0.82
(if female)
Schaeffner et al., 2012 (7) n ¼ 570, mean age ¼ 78.5 yrs, % male 57.2, % black ¼ 0,
mean weight ¼ 77.3 kg, mean GFR ¼ 60.3
*CrCl by Cockcroft-Gault was calculated twice, with weight deﬁned as actual body weight and as ideal body weight (based on Devine formula [15]). †k ¼ 0.7 for females and 0.9 for males;
a ¼ –0.329 for females and –0.411 for males.
BIS1 ¼ Berlin Initiative Study 1; CKD-EPI ¼ Chronic Kidney Disease Epidemiology Collaboration; CrCl ¼ creatinine clearance (ml/min); eGFR ¼ estimated glomerular ﬁltration rate (in ml/min/
1.73 m2); GFR ¼ glomerular ﬁltration rate; max ¼ maximum of SCr/k or 1; min ¼ minimum of Scr/k or 1; MDRD ¼ Modiﬁcation of Diet in Renal Disease; SCr ¼ serum creatinine (in mg/dl).
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2716concordance correlation coefﬁcient was used to as-
sess agreement between estimates, with standard
errors estimated with an assumption of asymptotic
normality after Fisher Z-transformation (18). Receiver
operating characteristic analysis was used to assess
the diagnostic discrimination of candidate eGFR es-
timates with respect to in-hospital outcomes, with
standard errors for the area under the receiving
operating characteristic estimates obtained by the
Delong method (19).
Patients were assigned to CKD stages based on
each of the eGFR estimates with the use of KDIGO
guidelines, with stage 1, 2, 3a, 3b, 4, and 5 deﬁned by
eGFR $90, 60 to 89, 45 to 59, 30 to 44, 15 to 29,
and <15 ml/min/1.73 m2, respectively (8). Confusion
matrices were used to determine the extent of
agreement in CKD staging by different eGFR esti-
mates. Agreement was assessed with Cohen’s kappa
without weighting. Net reclassiﬁcation index (NRI)
statistics were used to compare the diagnostic accu-
racy of CKD stage estimates between the eGFR can-
didates with respect to in-hospital outcomes (20).
To assess the extent to which candidate eGFR
estimates could potentially impact drug-dosing
recommendations, we constructed Venn diagrams
to compare how many patients would meet the
U.S. Food and Drug Administration–recommended
eGFR drug-dose–reduction cutoffs of <60, <50,
or <30 ml/min/1.73 m2 for tiroﬁban, eptiﬁbatide, and
bivalirudin, respectively (21). R version 3.0.3 was
used for this analysis (22).
RESULTS
Between 2010 and 2014, a total of 135,462 patients
underwent PCI at institutions participating in theBlue Cross Blue Shield of Michigan Cardiovascular
Consortium. Of these patients, 3,183 were missing
pre-procedural serum creatinine values, 3,357 were
undergoing hemodialysis before PCI, and 189 were
missing 1 or more variables required to estimate GFR
(age, weight, or height). A total of 6,657 patients met
1 or more exclusion criteria. The baseline demo-
graphic and clinical characteristics of the remaining
128,805 patients included in our overall cohort, as
well as the elderly subgroup, are presented in Table 2.
AKI occurred in 3.24% of patients, whereas NRD
occurred in 0.35%. A total of 1,790 patients (1.39%)
died before discharge. Transfusion was required for
2.98% of patients. In the elderly subgroup, rates of all
4 adverse outcomes were increased (Table 2). There
was signiﬁcant variability in the predicted eGFR
calculated with the different equations (Figure 1),
with median eGFRs of 89.0, 73.0, and 76.7 ml/min/
1.73 m2 for the Cockcroft-Gault, MDRD, and CKD-EPI
equations, respectively.
RECEIVER OPERATING CHARACTERISTIC ANALYSIS.
Results of the receiver operating characteristic anal-
ysis for the 4 endpoints can be found in Table 3. For
AKI, CKD-EPI produced an area under the curve of
0.741, which was signiﬁcantly greater than that pro-
duced with the MDRD and Cockcroft-Gault equations.
Receiver operating characteristic analysis for mortal-
ity demonstrated an area under the curve of 0.734 for
CKD-EPI, which was not signiﬁcantly different from
that of Cockcroft-Gault; however, it was signiﬁcantly
greater than that of MDRD. The area under the curve
of CKD-EPI for NRD was not signiﬁcantly different
from MDRD but was signiﬁcantly greater than that of
Cockcroft-Gault. For the endpoint of blood product
transfusions, Cockcroft-Gault had the largest area
TABLE 2 Baseline Demographics and Post-Procedural Outcomes
All Patients
(n ¼ 128,805)
Subgroup Age $70 yrs
(n ¼ 46,850)
Baseline demographics
Age, yrs 65.0  12.1 77.7  5.7
Female 33.52 41.30
White race 86.42 89.38
Black race 10.72 8.02
BMI, kg/m2 30.6  7.5 28.9  6.5
Hypertension 85.23 90.99
Diabetes mellitus 37.29 38.05
Prior heart failure 15.23 21.76
Prior peripheral artery disease 16.01 21.72
Current smoker within past year 29.42 10.21
Chronic lung disease 18.68 21.38
STEMI 14.87 10.84
NSTEMI/UA 61.78 62.72
Stable angina or other CAD presentation 23.36 26.44
Prior MI 34.94 36.00
Prior CABG 18.62 25.56
Prior PCI 45.06 47.65
Post-procedural outcomes
CABG 0.95 0.89
Death 1.39 2.20
NRD 0.35 0.47
Transfusion 2.98 4.69
Acute kidney injury 3.24 4.33
Values are mean  SD or %.
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery dis-
ease; MI ¼myocardial infarction; NRD¼ new requirement for dialysis; NSTEMI¼ non–ST-segment
elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment
elevation myocardial infarction; UA ¼ unstable angina.
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2717under the curve (0.713), which was signiﬁcantly
greater than that of MDRD and CKD-EPI.
CKD STAGE RECLASSIFICATION BY eGFR CATEGORIES
AND PREDICTION OF RISK. The eGFR calculated by
the MDRD and CKD-EPI equations classiﬁed patients
as being in the same CKD stage 84.69% of the time
(Figure 2). Of the 19,720 patients who were reclassi-
ﬁed by CKD-EPI compared with MDRD, 11.64% were
reclassiﬁed to a lower CKD stage (higher eGFR cate-
gory) and 3.66% to a higher CKD stage (lower eGFR
category). The results for the comparison of CKD-EPI
and Cockcroft-Gault found a much lower percentage
agreement (56.01%), and in this case, the vast ma-
jority of reclassiﬁcation by CKD-EPI placed patients
in a higher-severity CKD stage (34.14% in a lower
eGFR category and 9.85% in a higher eGFR category).
When Cockcroft-Gault was adjusted for body surface
area, agreement in classiﬁcation improved (71.02%),
but in this case, the reclassiﬁcations to lower- or
higher-severity CKD stages were similar (15.88% in a
higher eGFR category and 13.09% in a lower eGFR
category).
In the elderly subgroup, the highest agreement in
CKD classiﬁcation by eGFR also occurred in the CKD-
EPI and MDRD comparison (Online Figure 1), but
the majority of reclassiﬁcation by CKD-EPI moved
patients to a higher-severity CKD stage. Classiﬁ-
cations by BIS1 and CKD-EPI were in agreement
65.96% of the time, with the majority of reclassiﬁca-
tion by CKD-EPI placing patients in a lower CKD
stage (32.95%). Again, agreement between CKD-EPI
and Cockcroft-Gault was lowest.
In the general population cohort, reclassiﬁcation to
a higher or lower CKD stage by CKD-EPI was found
to more appropriately predict risk of AKI and NRD.
This is demonstrated by the statistically signiﬁcant
negative NRIs for reclassiﬁcation by MDRD and
Cockcroft-Gault compared with CKD-EPI (Figure 3).
For reclassiﬁcation by MDRD, the NRI was negative
in a statistically signiﬁcant fashion for AKI (6.21;
95% conﬁdence interval [CI]: 5.11 to 7.31) and NRD
(6.67; 95% CI: 3.85 to 9.50). Cockcroft-Gault
performed similarly. Reclassiﬁcation by MDRD also
resulted in a negative NRI for mortality and need for
transfusion; however, Cockcroft-Gault had a signiﬁ-
cantly positive NRI for mortality (9.71; 95% CI: 6.36 to
13.05) and transfusion (12.80; 95% CI: 10.52 to 15.07).
When Cockcroft-Gault was adjusted for body surface
area, the NRI results remained signiﬁcantly positive
for mortality (5.03; 95% CI: 2.17 to 7.89) and need
for transfusion (5.40; 95% CI: 3.44 to 7.36). For the
comparison of classiﬁcation with 2 weight deﬁni-
tions, Cockcroft-Gault (ideal body weight) had a
signiﬁcantly negative NRI for mortality but wassigniﬁcantly positive for AKI compared with
Cockcroft-Gault using actual body weight. In the
elderly subgroup, reclassiﬁcation of CKD stage by
BIS1 compared with CKD-EPI resulted in negative
NRIs for all outcomes (Online Figure 2).
VARIOUS ESTIMATIONS FOR GFR IMPACT ON DRUG
DOSING. Of the 128,805 patients in our general pop-
ulation cohort, 41,483 (32.2%), 24,659 (19.1%), and
4,261 (3.3%) were estimated by at least 1 equation to
have an eGFR <60, <50, and <30 ml/min/1.73 m2,
respectively; however, the degree to which all 3
equations were in agreement on this classiﬁcation
decreased as the eGFR cutoff value decreased. The 3
equations were in agreement on the classiﬁcation of
50.3% of patients to an eGFR <60 ml/min/1.73 m2,
whereas agreement occurred for 45.0% and 34.3% of
patients for the cutoffs of <50 and <30 ml/min/
1.73 m2, respectively. The distributions of pa-
tients with a low eGFR, as classiﬁed by 1 or more
methods, are described in the Venn diagrams
(Central Illustration). When the Cockcroft-Gault eGFR
FIGURE 1 Scatterplots of eGFR and CrCl by Various Formulas
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C-G ¼ Cockcroft-Gault; CKD-EPI ¼ Chronic Kidney Disease Epidemiology Collaboration; CrCl ¼ creatinine clearance; eGFR ¼ estimated
glomerular ﬁltration rate; MDRD ¼ Modiﬁcation of Diet in Renal Disease.
TABLE 3 Receiver Operating Characteristic Analysis of Outcomes With Glomerular
Filtration Rate Values Censored at 90 ml/min/1.73 m2
Outcome Comparing AUC to AUC
Nominal p Value
for Comparison
Signiﬁcant at
a ¼ 0.05 After
Bonferroni Adjustment for
Multiple Comparisons
AKI CKD-EPI 0.741 MDRD 0.735 <0.001 Yes
AKI CKD-EPI 0.741 C-G 0.708 <0.001 Yes
AKI MDRD 0.735 C-G 0.708 <0.001 Yes
NRD CKD-EPI 0.852 MDRD 0.856 0.002 No
NRD CKD-EPI 0.852 C-G 0.808 <0.001 Yes
NRD MDRD 0.856 C-G 0.808 <0.001 Yes
Transfusion CKD-EPI 0.695 MDRD 0.688 <0.001 Yes
Transfusion CKD-EPI 0.695 C-G 0.713 <0.001 Yes
Transfusion MDRD 0.688 C-G 0.713 <0.001 Yes
Death CKD-EPI 0.734 MDRD 0.725 <0.001 Yes
Death CKD-EPI 0.734 C-G 0.733 0.711 No
Death MDRD 0.725 C-G 0.733 0.151 No
AKI ¼ acute kidney injury; AUC ¼ area under the curve; C-G¼ Cockcroft-Gault; CKD-EPI¼ Chronic Kidney Disease
Epidemiology Collaboration; MDRD ¼ Modiﬁcation of Diet in Renal Disease; NRD ¼ new requirement for dialysis.
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2718was adjusted for body surface area, concordance
improved; however, the 3 equations still only agreed on
drug-dose adjustment in 62.9%, 56.2%, and 45.0% of
patients for eGFR cutoffs of <60, <50, and <30 ml/min/
1.73 m2, respectively (Online Figure 3).
DISCUSSION
The principal ﬁnding of our study is that there is
wide variation in the estimation of GFR among the
main equations used today, which leads to CKD stage
reclassiﬁcation in a large proportion of patients and
can have important implications regarding risk for
major adverse outcomes after PCI. Additionally, cal-
culation of eGFR by the various equations resulted in
large discrepancies in drug-dosing recommendations
for commonly used antiplatelet and antithrombotic
agents.
Our work expands on and integrates the extensive
literature regarding the clinical implications of CKD
staging on prediction of overall cardiovascular risk
FIGURE 2 Confusion Matrices of Patients Classiﬁed by CKD Stages by eGFR Categories
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BSA ¼ body surface area; CKD ¼ chronic kidney disease; G1 to G5 ¼ stage of CKD as deﬁned by eGFR category; other abbreviations as in
Figure 1.
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2719and risk of adverse outcomes after PCI with the
studies comparing the accuracy and risk prediction of
eGFR equations. Multiple studies have shown that
cardiovascular risk increases with decreasing eGFR
(23,24). In patients undergoing PCI, CKD is an inde-
pendent risk factor for all-cause mortality, bleeding,
and contrast-induced nephropathy, with the risk for
adverse events increasing with decreasing eGFR (1,2).
Therefore, accurate staging of CKD is of paramountimportance to the assessment of a patient’s risk for
adverse events with PCI. Our study demonstrates
that the selection of the eGFR equation can result
in signiﬁcant CKD restaging, with disagreement as
high as 45% between CKD-EPI and Cockcroft-
Gault and as high as 15% between the 2 currently
recommended equations (CKD-EPI and MDRD).
When CKD stage is used as a prognostic indicator,
the clinician must consider this discrepancy when
FIGURE 3 NRI Compared With CKD-EPI Using CKD Stages Deﬁned by eGFR and CrCl Values
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AKI ¼ acute kidney injury; BIS1 ¼ Berlin Initiative Study; NRD ¼ new requirement for dialysis; NRI ¼ net reclassiﬁcation index; other
abbreviations as in Figures 1 and 2.
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2720selecting an eGFR equation and appreciate how risk
assessment for an individual patient may hinge on
this decision.
Interestingly, although the BIS1 equation was
developed in the elderly and was shown to be more
accurate in its original cohort, our results do not
support its use in the elderly subpopulation given
the negative NRI values for all adverse events. This
discrepancy may be secondary to the development of
BIS1 in a relatively healthier patient cohort (14.9%
with previous myocardial infarction vs. 36% in our
study) and the equation having not yet been vali-
dated externally.
Currently, the KDIGO guidelines recommend the
use of the CKD-EPI equation because it has been
found to be more accurate, more precise, and
less biased than the MDRD equation (6,8). The
Cockcroft-Gault equation is not recommended be-
cause it was developed before standardization of
creatinine assays (8). However, regardless of these
guidelines, a recent survey demonstrated that there
is still wide variation among institutions providing
an automatic eGFR from serum creatinine values,
with 83% of reporting laboratories using the MDRD,
4% using Cockcroft-Gault, 2% using another equa-
tion, and 12% of responders being “unsure” of theequation used at their institution (10). Furthermore,
although physicians may rely on these automati-
cally reported eGFR values, pharmacists frequently
recalculate renal function using an alternative
equation, often the Cockcroft-Gault. The fact that
providers use different equations to estimate renal
function or are unaware of the equation they are
using increases the potential for error when estab-
lishing the dose for medications that could poten-
tially cause serious harm in patients with decreased
renal function.
In regard to renally dosed medications, the eGFR
equation selected to determine drug dosing in the
clinic ideally would be identical to the choice of
equation used in the drug’s original pharmacoki-
netic study; however, the U.S. Food and Drug
Administration currently has no clear guidelines for
equation selection in the pharmacokinetic studies
of novel medications (personal communication, FDA
Division of Drug Information, August 25, 2014) (25).
Instead, the choice of equation is determined per
drug company discretion, and many pharmacoki-
netic studies use the Cockcroft-Gault equation.
Since 2010, the U.S. Food and Drug Administration
has made a greater attempt to include informa-
tion on which equations are being used, but this
CENTRAL ILLUSTRATION Impact of eGFR Equation on Drug Dosing
 PERCENT OF PATIENTS SELECTED FOR eGFR-BASED DRUG DOSING ADJUSTMENT BY EQUATION
RECOMMENDATIONS TO INCREASE DRUG DOSING ACCURACY 
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The choice of estimated glomerular ﬁltration rate (eGFR) equation varies widely among institutions, physicians, and pharmacists, and the use of an inappropriate
equation could lead to large discrepancies in drug dosing and potential patient harm. Standardization of eGFR equation use among clinicians and new drug pharmaco-
kinetic design could clarify equation selection and reduce possible drug-dosing errors.
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2721information is not always readily available. To en-
sure appropriate dosage reductions, our study
results emphasize the importance of clear docu-
mentation of the choice of an eGFR equation in all
pharmacokinetic studies and determination of in-
dividual drug-dosing recommendations with that
same equation. Given the striking disagreements
in eGFR between the various equations and the
lack of consistent documentation of pharmacoki-
netic study design, our results may even argue that
it would beneﬁt our patients to enact a uniform
equation recommendation for all new drug devel-
opment. Because multiple studies have demon-
strated the improved accuracy of the CKD-EPI
equation for predicting true GFR, and because it
demonstrates better reclassiﬁcation for the renallybased outcomes of NRD and AKI, we would argue
for use of the CKD-EPI equation as the standard for
pharmacokinetic studies.
STUDY LIMITATIONS. First, our study’s purpose was
not to identify which equation most accurately pre-
dicts true GFR, but rather which stratiﬁes our pa-
tients in a way that best correlates with the risk of
adverse outcomes after PCI. Therefore, we had no
gold standard of true GFR with which to compare
our estimated GFRs for each patient. Multiple other
studies have investigated the accuracy, precision,
and bias of each equation, and we took their con-
clusions into account in our ﬁnal recommendations
for the use of CKD-EPI (6,8). In addition, there are
multiple deﬁnitions for AKI, and we would expect
the chosen deﬁnition to affect our results. We
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Esti-
mates of glomerular ﬁltration rate vary depending on
the equation used, which results in clinically impor-
tant differences in dose calculations for antiplatelet
and antithrombotic drugs administered to patients
with chronic kidney disease undergoing percutaneous
coronary interventions.
TRANSLATIONAL OUTLOOK: Prospective studies
are needed to determine the optimal method for
estimation of renal clearance of drugs used in patients
with chronic kidney disease undergoing cardiovascular
procedures.
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2722selected the deﬁnition of a serum creatinine increase
>0.5 mg/dl because we and others have shown its
superiority for predicting adverse events in patients
undergoing PCI (16,17).
CONCLUSIONS
Our study demonstrates that not only is there great
heterogeneity in eGFR values calculated by the most
widely used equations today, but this variability af-
fects risk classiﬁcation for adverse events with PCI.
Our data support the use of the CKD-EPI equation
in the evaluation of patients before PCI, given its
improved accuracy and risk classiﬁcation for AKI
and NRD. Finally, our data suggest that transparency
and standardization for the estimation of GFR for
pharmacokinetic studies could potentially lead to
improved dosage recommendations and better out-
comes for our patients.
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